Cor Vasa 2023, 65(1):77-81 | DOI: 10.33678/cor.2023.004

(Why to use fixed dose perindopril, bisoprolol combination in hypertonics with CHD?)

Ondřej Petrák

Centrum pro výzkum, diagnostiku a léčbu arteriální hypertenze, III. interní klinika, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze, Praha

Cardiovascular disease is the leading cause of mortality worldwide. Arterial hypertension is one of the earliest risk factors of atherosclerosis and early intervention significantly reduces cardiovascular morbidity and mortality. We have to tailor the treatment to individual patients according to their hypertension subclass and their cardiovascular and metabolic risk profile. The fixed combination has a number of advantages, from better and faster achievement of blood pressure target values, through fewer side effects to improved adherence to treatment. The combination of a beta-blocker (bisoprolol) and an ACE inhibitor (perindopril) has complementary effects on the sympathetic nervous system and the renin-angiotensin-aldosterone axis. The combination of these drugs effectively reduces blood pressure and heart rate, which improves the cardiovascular prognosis of selected patients. The article is devoted to the indications of these drugs in patients both in the treatment of uncomplicated hypertension and in secondary prevention in patients with ischemic heart disease. The emphasis is placed especially on the position of beta-blockers.

Keywords: Arterial hypertension, Bisoprolol, Ischemic heart disease, Fixed dose combination, Perindopril

Received: January 12, 2023; Revised: January 12, 2023; Accepted: January 16, 2023; Published: March 1, 2023  Show citation